According to an article published online by the Telegraph, scientists at the University of Southampton have developed a new drug that works by increasing the ability of the immune system to recognise and attack tumours. A £5 million European Union funded trial of the new treatment is due to start next year.
“Some cancers are able to switch the immune cells off. We have been working on a drug that effectively puts the foot on the accelerator to rev up the immune system… If we use this with a vaccine we can steer the immune cells and train them to target the cancer.”
Prof. Martin Glennie will be providing delegates at SMi’s 2nd annual Cancer Vaccines conference with a unique insight on anti-cancer immunity. The presentation titled: Developing Antibodies to Stimulate Anti-Cancer Immunity will:
- Discuss the nature of anti-cancer immunity and the ability of the immune system to recognise most types of cancer.
- Explore how antibodies recognising key members of the TNFR super family can stimulate T-cell responses against cancer.
- Show that these immuno stimulating antibodies need to engage Fc receptors in the host to provide sufficient cross-linking of the various TNFR’s.
- Discuss how antibody engineering will be used to optimise cross-linking activity in vivo.
Cancer Vaccines – 18-19 September 2013, London UK
To meet Prof. Martin Glennie and for further information visit the event homepage at: www.smi-online.co.uk/goto/2013cancervaccinesevent74.asp
SMi Group Ltd